Saturday 17 October 2026 Export CANF’s income statement to Excel — free account

Can-Fite Biopharma Ltd

Can-Fite Biopharma Ltd’s revenue for fiscal 2025 (year ended December 2025) was $405,000.00, down 39.9% from fiscal 2024.

1.76 0.09 −4.86%

Follow CANF

Alert me

Market cap: $5.6M
P/E: 0.0×
Fwd P/E: −1.7×
Dividend yield: —
F-score: 2/9
Altman Z: −27.99
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 5.61

Revenue 0.78

Net Income (13.43)

Free Cash Flow (19.15)

Net Debt (7.04)

Current Ratio 3.60

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.72)

P/S ratio 0.45

P/B ratio 0.07

Past 5Y EPS Growth —

This Y EPS Growth 65.83%

Next Y EPS Growth 55.39%

Next Y revenue growth (67.82%)

Next 5Y EPS Growth 52.50%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.04%

10-year low 10-year high

P/B against its own 10 years 0.04%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	9	8	9	7
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	10	9	9	8

	2023	2024	2025	Q'26
Payables	1	2	2	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	2	2	3	2

Compound Annual Growth %

	10y	5y	3y
Sales	9.39%	(11.90%)	(20.63%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(6.06%)	(1.64%)	7.73%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	0
’24	—	—	—	—	1
’23	0	—	—	—	1
’22	0	0	0	0	1
’21	0	0	0	0	1
’20	0	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(9)
’24	—	—	—	—	(8)
’23	—	—	—	—	(8)
’22	—	—	—	—	(11)
’21	—	—	—	—	(10)
’20	—	—	—	—	(12)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	(5)	—	—	—
’25	—	(5)	—	—	(9)
’24	—	(4)	—	—	(8)
’23	—	(5)	—	—	(8)
’22	—	(6)	—	—	(11)
’21	—	(3)	—	—	(10)
’20	—	(8)	—	—	(12)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(11.94)
’24	—	—	—	—	(21.80)
’23	(13.00)	—	—	—	(35.80)
’22	(18.00)	0.00	0.00	0.00	(74.80)
’21	(24.00)	(0.01)	(0.01)	(0.01)	(136.00)
’20	(144.00)	(0.01)	(0.01)	(0.01)	(240.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	5,550.00	3,720.00	3,000.00	380.00	216.00	188.00	116.00	30.40	25.80	3.40	Analyst estimates 2026–2028 Powerpack
	High	10,770.00	8,010.00	8,250.00	4,860.00	800.00	878.00	290.00	137.20	93.80	46.60
People
People	Employees	7	7	7	8	8	8	8	5	5	5
	Revenue/emp, $m	0.02	0.11	0.55	0.25	0.10	0.11	0.10	0.15	0.13	0.08
Income, $m
Income, $m	Revenue	0	1	4	2	1	1	1	1	1	0
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(7)	(6)	(7)	(13)	(14)	(13)	(10)	(8)	(8)	(10)
	EBT margin, %	(4,114.71)	(811.66)	(171.91)	(621.31)	(1,892.92)	(1,478.90)	(1,255.93)	(1,027.46)	(1,169.14)	(2,426.67)
	Net income	(7)	(6)	(7)	(13)	(14)	(13)	(10)	(8)	(8)	(10)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	36.17	146.11	587.69	142.10	12.78	9.25	5.96	3.49	1.86	0.49
	Earnings	(1,499.25)	(899.55)	(1,019.49)	(881.74)	(240.00)	(136.00)	(74.80)	(35.80)	(21.80)	(11.94)
	Cash flow	(1,900.21)	(1,661.48)	(639.23)	(775.10)	(202.06)	(106.92)	(79.42)	(39.61)	(21.06)	(10.87)
	Capex	(2.13)	(5.37)	(5.08)	(0.21)	(0.44)	(0.12)	(0.07)	(0.01)	(0.01)	0.00
	Free cash flow	(1,902.34)	(1,666.85)	(644.31)	(775.31)	(202.50)	(107.04)	(79.49)	(39.62)	(21.07)	(10.88)
	Book value	824.68	928.52	463.85	170.77	101.74	155.99	32.88	29.30	14.99	6.79
	Shares, m	0	0	0	0	0	0	0	0	0	1
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	138.30	126.29	415.13	4.04	10,545.83	6,107.14	456.31	10.49	8.26	1.01
	P/B	3.28	4.72	107.95	5.50	1,336.03	362.48	80.60	1.55	2.58	0.19
	EV/Sales	70.59	81.55	410.17	1.73	10,534.99	6,084.72	446.20	0.25	2.16	(7.31)
	EV/FCF	(0.93)	(1.05)	(19.06)	(0.12)	(360.26)	(279.57)	(15.48)	(0.01)	(0.09)	0.28
Cash, $m
Cash, $m	Operating cash flow	(9)	(9)	(4)	(11)	(12)	(10)	(11)	(8)	(8)	(9)
	Capex	0	0	0	0	0	0	0	0	0	0
	Free cash flow	(9)	(9)	(4)	(11)	(12)	(10)	(11)	(8)	(8)	(9)
Balance, $m
Balance, $m	Working capital	8	5	5	4	8	17	7	8	7	7
	Total debt	—	—	—	0	0	0	0	—	—	—
	Net debt	(8)	(4)	(4)	(3)	(8)	(19)	(8)	(9)	(8)	(9)
	Shareholders’ equity	4	5	3	2	6	14	4	6	5	6
Returns, %
Returns, %	ROA	(49.68)	(71.28)	(84.43)	(156.58)	(171.31)	(102.13)	(68.89)	(79.22)	(82.47)	(105.48)
	ROIC	0.00	(297.59)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(96.34)	(142.61)	(163.68)	(462.71)	(355.99)	(148.66)	(107.91)	(142.49)	(134.94)	(178.24)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2023

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ALZN Alzamend Neuro, Inc.	$6.2M	— (loss-making)	—	—	n/m	+51.82% (above 0%: growing)	0.00%	0.00%	Compare
NRSN NeuroSense Therapeutics Ltd.	$6.0M	— (loss-making)	—	—	n/m	−23,458.82% (below 0%: shrinking)	—	0.00%	Compare
IMNN Imunon, Inc.	$6.0M	— (loss-making)	— (loss-making)	0.00%	n/m	−4.24% (below 0%: shrinking)	0.00%	0.00%	Compare
ORGS Orgenesis Inc.	$5.7M	— (loss-making)	1.0×	+82.42% (above 0%: growing)	n/m	−317.93% (below 0%: shrinking)	2,780.73%	(6,044.52%)	Compare
CANF Can-Fite Biopharma Ltd	$5.6M	— (loss-making)	— (loss-making)	−1.18% (below 0%: shrinking)	n/m	+12.63% (above 0%: growing)	0.00%	0.00%
BGMS Bio Green Med Solution, Inc.	$5.5M	— (loss-making)	— (loss-making)	+3,260.00% (above 0%: growing)	n/m	+66.67% (above 0%: growing)	23.51%	(124.40%)	Compare
CELZ Creative Medical Technology Holdings, Inc.	$5.4M	— (loss-making)	— (loss-making)	0.00%	n/m	−27.05% (below 0%: shrinking)	66.67%	0.00%	Compare
CDIO Cardio Diagnostics Holdings, Inc.	$5.2M	— (loss-making)	— (loss-making)	−28.00% (below 0%: shrinking)	n/m	+15.58% (above 0%: growing)	100.00%	(27,742.59%)	Compare
PULM Pulmatrix, Inc.	$5.2M	— (loss-making)	— (loss-making)	−99.86% (below 0%: shrinking)	n/m	+41.26% (above 0%: growing)	100.00%	0.00%	Compare
Median of peers	$5.6M	—	—	0.00%	—	+5.67%	66.67%	0.00%

All 614 Biotechnology stocks →

Can-Fite Biopharma Ltd (CANF) key facts

Concern: Can-Fite Biopharma Ltd’s revenue for fiscal 2025 (year ended December 2025) was $405,000.00, down 39.9% from fiscal 2024.
Can-Fite Biopharma Ltd (CANF) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, CANF traded at $1.76, a market capitalization of $5.6 million.
Return on equity was −178.2% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −27.99 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.